InflaRx rises on US FDA's emergency use authorization for COVID injection

Inflarx NV

04/04/2023 22:12

** U.S.-listed shares of Germany-based biopharma company
InflaRx NV  IF0G.F   IFRX.O  rise ~11% to $4.19 after the bell
    ** Company receives U.S. FDA's emergency use authorization
for vilobelimab to treat critically ill COVID-19 patients
    ** The injection is authorized for the treatment of
hospitalized COVID patients when initiated within 48 hours of
receiving artificial life support
    ** Vilobelimab, also known as Gohibic, controls a protein
that plays an important and often harmful role in the body's
immune response
    ** IFRX continues discussions with FDA to discuss next steps
toward submitting application for full approval
    ** Stock up ~21% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))